JOURNAL OF RESEARCH IN PHARMACY, vol.26, no.3, pp.641-654, 2022 (ESCI)
A series of novel 2-(2-thienylcarbonyl)hydrazono-3-alkyl/aryl-4-thiazolidinone (2a-f), 2-(2-thienyl)-5-[(4-bromophenyl)amino]-1,3,4-oxadiazole (3), 2-aryl-3-(2-thienylcarbonyparnino-4-thiazolidinone (5a-h) and 2-aryl-3-(2-thienylcarbonyDamino-5-methyl-4-thiazolidinone (6a-h) were designed and synthesized. The structural elucidations of the novel compounds were performed by IR, H-1-NMR, mass and elemental analysis. The compounds were evaluated for their antimycobacterial and antifungal activities. According to the biological activity studies activities of the compounds, 2f (MIC: >12.5 mu g/ml, 76% inhibition), 3 (MIC: >12.5 mu g/ml, 43% inhibition), and 5c (MIC: >12.5 mu g/ml, 38% inhibition), displayed antimycobacterial activity. 2b (MIC: 25 mu g/ml) displayed antifungal activity against T. rubrum. Besides, x-ray crystallography studies were performed to illuminate the structure of 2e. Consequently, the obtained results relvealed that 2f, 3 and 5c present a leading structure for future drug development due to its straightforward synthesis and relevant bioactivity.